Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMilitary Medical Clinical Center of the Southern Region, Ukraine
About this trial
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
Eligibility criteria
Qualifiers
Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
Ability to provide informed consent (for prospective participants).
Disqualifiers
Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
Incomplete diagnostic data preventing OC26 scoring.
Prior pancreatic surgery altering diagnostic interpretation.
Trial design
Treatments tested in this trial
- No intervention (observational study)
Treatment groups
82 Participants
are divided into 1 treatment groupLocations
2Military Medical Clinical Center of the Southern Region Odesa Ukraine
Military Medical Clinical Center of the Southern Region Odesa Ukraine
Sponsors and collaborators
Military Medical Clinical Center of the Southern Region, Ukraine
Lead sponsor
Source ClinicalTrials.gov